Treatment patterns of agitation associated with Alzheimer's dementia (AAD) patients in Canada.

OBJECTIVES

Explore treatment patterns of Canadian patients with AAD to understand variability in clinical management.

DESIGN

This retrospective study used public claims data from Ontario and New Brunswick in IQVIA databases.

SETTING

Inferred patients with AAD were identified through claims for cognitive enhancers and medications used off-label to treat AAD, i.e., antipsychotics (AP), anticonvulsants (AC), antidepressants (ADT), benzodiazepines (benzo).

PARTICIPANTS

Patients (≥55 years) were identified between 2011-2018, indexed on their first AP/AC/AD/benzo and followed until the earlier of their fourth line (4L) of therapy or September 30, 2023. An all-history lookback to 2003 was used to ensure no prior claims for these therapies.

MEASUREMENTS: Descriptive analyses explored treatment utilization patterns.

RESULTS

23,732 patients with AAD were identified, mostly from Ontario (98.7%). Patients with AAD tended to move to long-term care, with these increasing with more treatment trials from 24% (1 L therapy) to 54% (4 L therapy). Patients received between 500 and 2000 unique combinations across therapy lines. Citalopram, escitalopram, gabapentin, lorazepam, mirtazapine, pregabalin, quetiapine, risperidone, sertraline, and trazodone ranked in the top 10 therapies. Risperidone accounted for 7.2% of claims and ranked as the 6th most common 1 L therapy. Although trazodone remained the most common therapy for patients with AAD, it had one of the lowest persistence rates. Most patients remained on their 3 L - 4 L therapy, and ≥ 80% were adherent across all therapy lines. Average daily doses were lower than those described in the product monographs.

CONCLUSIONS

AAD treatment varies widely, underscoring the need for approved treatments and enhanced clinical education.

CLINICAL TRIAL NUMBER: Not applicable.